Boundless Bio, Inc. Common Stock (BOLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Boundless Bio, Inc. Common Stock (BOLD) has a cash flow conversion efficiency ratio of -0.093x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.20 Million) by net assets ($110.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Boundless Bio, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Boundless Bio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Boundless Bio, Inc. Common Stock carry for a breakdown of total debt and financial obligations.
Boundless Bio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boundless Bio, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
0.013x |
|
Lion Industries Corporation Bhd
KLSE:4235
|
-0.061x |
|
Censof Holdings Bhd
KLSE:5195
|
0.051x |
|
Aytu BioScience Inc
NASDAQ:AYTU
|
0.259x |
|
Pamapol S.A.
WAR:PMP
|
-0.041x |
|
Ovaro Kiinteistosijoitus Oyj
HE:OVARO
|
-0.048x |
|
Microbix Biosystems Inc.
TO:MBX
|
0.003x |
|
Zenith Minerals Ltd
AU:ZNC
|
-0.078x |
Annual Cash Flow Conversion Efficiency for Boundless Bio, Inc. Common Stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of Boundless Bio, Inc. Common Stock from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see BOLD market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $150.64 Million | $-60.84 Million | -0.404x | -209.54% |
| 2023-12-31 | $-127.08 Million | $-46.85 Million | 0.369x | -23.93% |
| 2022-12-31 | $-81.70 Million | $-39.60 Million | 0.485x | -20.38% |
| 2021-12-31 | $-38.19 Million | $-23.25 Million | 0.609x | +349.62% |
| 2018-12-31 | $442.75 Million | $-107.98 Million | -0.244x | +54.81% |
| 2017-12-31 | $156.60 Million | $-84.51 Million | -0.540x | -31.42% |
| 2016-12-31 | $119.37 Million | $-49.02 Million | -0.411x | -- |
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene ampli… Read more